These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 39352553)
1. Immunotherapy response and resistance in patients with advanced uveal melanoma: a retrospective cohort study. Maurer A; Clerici G; Schaab JA; Cheng PF; Mihic-Probst D; Mader C; Messerli M; Huellner MW; Dummer R; Dimitriou F Clin Exp Med; 2024 Oct; 24(1):234. PubMed ID: 39352553 [TBL] [Abstract][Full Text] [Related]
2. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone. Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924 [TBL] [Abstract][Full Text] [Related]
3. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis. Yang Y; Chen W; Dong L; Duan L; Gao P Clin Transl Oncol; 2024 Oct; 26(10):2488-2502. PubMed ID: 38625495 [TBL] [Abstract][Full Text] [Related]
4. Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study. Léna H; Greillier L; Cropet C; Bylicki O; Monnet I; Audigier-Valette C; Falchero L; Vergnenègre A; Demontrond P; Geier M; Guisier F; Hominal S; Locher C; Corre R; Chouaid C; Ricordel C; Lancet Respir Med; 2024 Oct; ():. PubMed ID: 39486424 [TBL] [Abstract][Full Text] [Related]
5. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early-stage Hodgkin's lymphoma. Goldkuhle M; Kreuzberger N; von Tresckow B; Eichenauer DA; Specht L; Monsef I; Skoetz N Cochrane Database Syst Rev; 2024 Dec; 12(12):CD007110. PubMed ID: 39620432 [TBL] [Abstract][Full Text] [Related]
6. Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study. Hamid O; Hassel JC; Shoushtari AN; Meier F; Bauer TM; Salama AKS; Kirkwood JM; Ascierto PA; Lorigan PC; Mauch C; Orloff M; Evans TRJ; Holland C; Edukulla R; Abedin SE; Middleton MR J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37286303 [TBL] [Abstract][Full Text] [Related]
11. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences. Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159 [TBL] [Abstract][Full Text] [Related]
12. Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter propensity score-matching analysis. Li Y; Guo J; Liu W; Pang H; Song Y; Wu S; Zhang F; Yan D; Chen J; An C; Li C Hepatol Int; 2024 Aug; 18(4):1286-1298. PubMed ID: 38717693 [TBL] [Abstract][Full Text] [Related]
13. Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study. Schadendorf D; Lord-Bessen J; Ejzykowicz F; Shi L; Yu P; Srinivasan S Eur J Cancer; 2024 Dec; 213():115099. PubMed ID: 39520835 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Bossi A; Foulon S; Maldonado X; Sargos P; MacDermott R; Kelly P; Fléchon A; Tombal B; Supiot S; Berthold D; Ronchin P; Kacso G; Salem N; Calabro F; Berdah JF; Hasbini A; Silva M; Boustani J; Ribault H; Fizazi K; Lancet; 2024 Nov; 404(10467):2065-2076. PubMed ID: 39580202 [TBL] [Abstract][Full Text] [Related]
15. Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer. Andre T; Elez E; Van Cutsem E; Jensen LH; Bennouna J; Mendez G; Schenker M; de la Fouchardiere C; Limon ML; Yoshino T; Li J; Lenz HJ; Manzano Mozo JL; Tortora G; Garcia-Carbonero R; Dahan L; Chalabi M; Joshi R; Goekkurt E; Braghiroli MI; Cil T; Cela E; Chen T; Lei M; Dixon M; Abdullaev S; Lonardi S; N Engl J Med; 2024 Nov; 391(21):2014-2026. PubMed ID: 39602630 [TBL] [Abstract][Full Text] [Related]
16. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Llovet JM; Kudo M; Merle P; Meyer T; Qin S; Ikeda M; Xu R; Edeline J; Ryoo BY; Ren Z; Masi G; Kwiatkowski M; Lim HY; Kim JH; Breder V; Kumada H; Cheng AL; Galle PR; Kaneko S; Wang A; Mody K; Dutcus C; Dubrovsky L; Siegel AB; Finn RS; Lancet Oncol; 2023 Dec; 24(12):1399-1410. PubMed ID: 38039993 [TBL] [Abstract][Full Text] [Related]
17. Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma. Ascierto PA; Mandalà M; Ferrucci PF; Guidoboni M; Rutkowski P; Ferraresi V; Arance A; Guida M; Maiello E; Gogas H; Richtig E; Quaglino P; Lebbé C; Helgadottir H; Queirolo P; Spagnolo F; Tucci M; Del Vecchio M; Gonzalez-Cao M; Minisini AM; De Placido S; Sanmamed MF; Casula M; Bulgarelli J; Pisano M; Piccinini C; Piccin L; Cossu A; Mallardo D; Paone M; Vitale MG; Melero I; Grimaldi AM; Giannarelli D; Palmieri G; Dummer R; Sileni VC NEJM Evid; 2024 Oct; 3(10):EVIDoa2400087. PubMed ID: 39315864 [TBL] [Abstract][Full Text] [Related]
18. Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory microsatellite stable non-liver metastatic colorectal cancer: A phase I nonrandomized clinical trial. Xiao A; Li X; Wang C; Ye J; Fakih M Eur J Cancer; 2024 Dec; 213():115111. PubMed ID: 39504677 [TBL] [Abstract][Full Text] [Related]
19. What Are the Functional, Radiographic, and Survivorship Outcomes of a Modified Cup-cage Technique for Pelvic Discontinuity? Mu W; Xu B; Wahafu T; Wang F; Guo W; Zou C; Cao L Clin Orthop Relat Res; 2024 Dec; 482(12):2149-2160. PubMed ID: 38991223 [TBL] [Abstract][Full Text] [Related]
20. Comparison of cognitive behaviour therapy versus activity management, both delivered remotely, to treat paediatric chronic fatigue syndrome/myalgic encephalomyelitis: the UK FITNET-NHS RCT. Crawley E; Anderson E; Cochrane M; Shirkey BA; Parslow R; Hollingworth W; Mills N; Gaunt D; Treneman-Evans G; Rai M; Macleod J; Kessler D; Pitts K; Cooper S; Loades M; Annaw A; Stallard P; Knoop H; Van de Putte E; Nijhof S; Bleijenberg G; Metcalfe C Health Technol Assess; 2024 Oct; 28(70):1-134. PubMed ID: 39485730 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]